While obinutuzumab has been a first‐line therapy for follicular lymphoma [235, 236], a preclinical animal trial in lupus mice confirmed that obinutuzumab greatly relieved renal damage, lowered anti‐RNA autoantibodies and activated CD4 T cells compared with RTX [178]. This evidence concerns the gene CD4 and systemic lupus erythematosus.